[1]
|
Ohgaki, H. and Kleihues, P. (2009) Genetic Alterations and Signaling Pathways in the Evolution of Gliomas. Cancer Science, 100, 2235-2241.
http://dx.doi.org/10.1111/j.1349-7006.2009.01308.x
|
[2]
|
Vargo, M. (2011) Brain Tumor Rehabilitation. American Journal of Physical Medicine & Rehabilitation, 90, S50-S62. http://dx.doi.org/10.1097/PHM.0b013e31820be31f
|
[3]
|
Sanai, N. and Berger, M.S. (2008) Glioma Extent of Resection and Its Impact on Patient Outcome. Neurosurgery, 62, 753-764.
http://dx.doi.org/10.1227/01.neu.0000318159.21731.cf
|
[4]
|
Ammirati, M., Vick, N., Liao, Y.L., et al. (1987) Effect of the Extent of Surgical Resection on Survival and Quality of Life in Patients with Supratentorial Glioblastomas and Anaplastic Astrocytomas. Neurosurgery, 21, 201-206.
http://dx.doi.org/10.1227/00006123-198708000-00012
|
[5]
|
Kelly, P.J., Daumas-Duport, C., Kispert, D.B., et al. (1987) Imaging-Based Stereotaxic Serial Biopsies in Untreated Intracranial Glial Neoplasms. Journal of Neurosurgery, 66, 865-874.
http://dx.doi.org/10.3171/jns.1987.66.6.0865
|
[6]
|
Dandy, W.E. (1928) Removal of Right Cerebral Hemisphere for Certain Tumors with Hemiplegia: Preliminary Report. The Journal of the American Medical Association, 90, 823.
http://dx.doi.org/10.1001/jama.1928.02690380007003
|
[7]
|
Stupp, R., Mason, W.P., van den Bent, M.J., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996. http://dx.doi.org/10.1056/NEJMoa043330
|
[8]
|
Stupp, R., Tonn, J.-C., Brada, M., et al. (2010) High-Grade Malignant Glioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 21, v190-v193. http://dx.doi.org/10.1093/annonc/mdq187
|
[9]
|
Herbert, C., Williams, M., Sawyer, H., et al. (2011) Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice. Journal of Clinical Oncology, 23, 372-373. http://dx.doi.org/10.1016/j.clon.2011.01.157
|
[10]
|
Clarke, J., Butowski, N. and Chang, S. (2010) Recent Advances in Therapy for Glioblastoma. Archives of Neurology, 67, 279-283. http://dx.doi.org/10.1001/archneurol.2010.5
|
[11]
|
Quick, A., Patel, D., Hadziahmetovic, M., et al. (2010) Current Therapeutic Paradigms in Glioblastoma. Reviews on Recent Clinical Trials, 5, 14-27.
http://dx.doi.org/10.2174/157488710790820544
|
[12]
|
Sherriff, J., Tamangani, J., Senthi,l L., et al. (2013) Patterns of Relapse in Glioblastoma Multiforme Following Concomitant Chemoradiotherapy with Temozolomide. The British Journal of Radiology, 86, Article ID: 20120414. http://dx.doi.org/10.1259/bjr.20120414
|
[13]
|
Senft, C., Forster, M.-T., Bink, A., et al. (2012) Optimizing the Extent of Resection in Eloquently Located Gliomas by Combining Intraoperative MRI Guidance with Intraoperative Neurophysiological Monitoring. Journal of Neuro-Oncology, 109, 81-90.
http://dx.doi.org/10.1007/s11060-012-0864-x
|
[14]
|
Barnett, G.H. (1999) The Role of Image-Guided Technology in the Surgical Planning and Resection of Gliomas. Journal of Neuro-Oncology, 42, 247-258.
http://dx.doi.org/10.1023/A:1006138609201
|
[15]
|
Schulder, M. and Liang, D. (2012) The Role of Intraoperative Magnetic Resonance Imaging in Glioma Surgery. Surgical Neurology International, 3, 320.
http://dx.doi.org/10.4103/2152-7806.103029
|
[16]
|
Stummer, W., Pichlmeier, U., Meinel, T., et al. (2006) Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial. The Lancet Oncology, 7, 392-401.
http://dx.doi.org/10.1016/S1470-2045(06)70665-9
|
[17]
|
Senft, C., Bink, A., Franz, K., et al. (2011) Intraoperative MRI Guidance and Extent of Resection in Glioma Surgery: A Randomised, Controlled Trial. The Lancet Oncology, 12, 997-1003. http://dx.doi.org/10.1016/S1470-2045(11)70196-6
|
[18]
|
Dobkin, B.H. (2005) Rehabilitation after Stroke. The New England Journal of Medicine, 352, 1677-1684. http://dx.doi.org/10.1056/NEJMcp043511
|
[19]
|
Kos, N., Kos, B. and Benedicic, M. (2016) Early Medical Rehabilitation after Neurosurgical Treatment of Malignant Brain Tumours in Slovenia. Radiology and Oncology, 50, 139-144.
|
[20]
|
Walker, M.D., Alexander, E., Hunt, W.E., et al. (1978) Evaluation of BCNU and/or Radiotherapy in the Treatment of Anaplastic Gliomas. A Cooperative Clinical Trial. Journal of Neuro-Oncology, 49, 333-343. http://dx.doi.org/10.3171/jns.1978.49.3.0333
|
[21]
|
Lawrence, Y.R., Wang, M., Dicker, A.P., et al. (2011) Early Toxicity Predicts Long-Term Survival in High-Grade Glioma. British Journal of Cancer, 104, 1365-1371.
http://dx.doi.org/10.1038/bjc.2011.123
|
[22]
|
Kondoh, T., Morishita, A., Kamei, M., et al. (2003) Moyamoya Syndrome after Prophylactic Cranial Irradiation for Acute Lymphocytic Leukemia. Pediatric Neurosurgery, 39, 264-269.
http://dx.doi.org/10.1159/000072872
|
[23]
|
Douw, L., Klein, M., Fagel, S.S., et al. (2009) Cognitive and Radiological Effects of Radiotherapy in Patients with Low-Grade Glioma: Long-Term Follow-Up. The Lancet Oncology, 8, 810-818. http://dx.doi.org/10.1016/S1474-4422(09)70204-2
|
[24]
|
Crossen, J.R., Garwood, D., Glatstein, E. and Neuwelt, E.A. (1994) Neurobehavioral Sequelae of Cranial Irradiation in Adults: A Review of Radiation-Induced Encephalopathy. Journal of Clinical Oncology, 12, 627-642.
|
[25]
|
Kortmann, R.-D., Timmermann, B., Taylor, R.E., et al. (2003) Current and Future Strategies in Radiotherapy of Childhood Low-Grade Glioma of the Brain: Part II: Treatment-Related Late Toxicity. Strahlentherapie und Onkologie, 179, 585-597.
http://dx.doi.org/10.1007/s00066-003-8104-0
|
[26]
|
Nandagopal, R., Laverdière, C., Mulrooney, D., et al. (2007) Endocrine Late Effects of Childhood Cancer Therapy: A Report from the Children’s Oncology Group. Hormone Research in Paediatrics, 69, 65-74. http://dx.doi.org/10.1159/000111809
|
[27]
|
Merchant, T.E., Kiehna, E.N., Li, C., et al. (2005) Radiation Dosimetry Predicts IQ after Conformal Radiation Therapy in Pediatric Patients with Localized Ependymoma. International Journal of Radiation Oncology Biology Physics, 63, 1546-1554.
http://dx.doi.org/10.1016/j.ijrobp.2005.05.028
|
[28]
|
Ulff, E., Maroti, M., Serup, J. and Falkmer, U. (2013) A Potent Steroid Cream Is Superior to Emollients in Reducing Acute Radiation Dermatitis in Breast Cancer Patients Treated with Adjuvant Radiotherapy. A Randomised Study of Betamethasone versus Two Moisturizing Creams. Radiotherapy & Oncology, 108, 287-292.
http://dx.doi.org/10.1016/j.radonc.2013.05.033
|
[29]
|
Kazda, T., Jancalek, R., Pospisil, P., et al. (2014) Why and How to Spare the Hippocampus during Brain Radiotherapy: The Developing Role of Hippocampal Avoidance in Cranial Radiotherapy. Radiotherapy & Oncology, 9, 139.
http://dx.doi.org/10.1186/1748-717X-9-139
|
[30]
|
van den Bent, M.J. (2003) Phase II Study of First-Line Chemotherapy with Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology, 21, 2525-2528. http://dx.doi.org/10.1200/JCO.2003.12.015
|
[31]
|
Jordan, K., Sippel, C. and Schmoll, H.-J. (2007) Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations. The Oncologist, 12, 1143-1150. http://dx.doi.org/10.1634/theoncologist.12-9-1143
|
[32]
|
Chen, R., Cohen, A.L. and Colman, H. (2016) Targeted Therapeutics in Patients with High-Grade Gliomas: Past, Present, and Future. Current Treatment Options in Oncology, 17, 42. http://dx.doi.org/10.1007/s11864-016-0418-0
|
[33]
|
Okura, H., Smith, C.A. and Rutka, J.T. (2014) Gene Therapy for Malignant Glioma. Molecular and Cellular Therapies, 2, 21. http://dx.doi.org/10.1186/2052-8426-2-21
|
[34]
|
Osoba, D., Brada, M, Prados, M.D. and Yung, W.A. (2000) Effect of Disease Burden on Health-Related Quality of Life in Patients with Malignant Gliomas. Journal of Neuro-Oncology, 2, 221-228. http://dx.doi.org/10.1215/15228517-2-4-221
|
[35]
|
Wang, H., Xu, T., Jiang, Y., et al. (2015) The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas. Neoplasia, 17, 239-255.
http://dx.doi.org/10.1016/j.neo.2015.02.002
|
[36]
|
Kleinschmidt-DeMasters, B.K., Aisner, D.L. and Foreman, N.K. (2015) BRAF VE1 Immunoreactivity Patterns in Epithelioid Glioblastomas Positive for BRAF V600E Mutation. The American Journal of Surgical Pathology, 39, 528-540.
http://dx.doi.org/10.1097/PAS.0000000000000363
|
[37]
|
Robinson, G.W., Orr, B.A. and Gajjar, A. (2014) Complete Clinical Regression of a BRAF V600E-Mutant Pediatric Glioblastoma Multiforme after BRAF Inhibitor Therapy. BMC Cancer, 14, 258.
|
[38]
|
Prins, R.M., Wang, X., Soto, H., et al. (2013) Comparison of Glioma-Associated Antigen Peptide-Loaded Versus Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination in Malignant Glioma Patients. Journal of Immunotherapy, 36, 152-157.
http://dx.doi.org/10.1097/CJI.0b013e3182811ae4
|
[39]
|
Heimberger, A.B., Hlatky, R., Suki, D., et al. (2005) Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research: American Association for Cancer Research, 11, 1462-1466.
http://dx.doi.org/10.1158/1078-0432.CCR-04-1737
|
[40]
|
Malkki, H. (2016) Trial Watch: Glioblastoma Vaccine Therapy Disappointment in Phase III trial. Nature Reviews Neurology, 12, 190-190. http://dx.doi.org/10.1038/nrneurol.2016.38
|
[41]
|
Hou, Y., Kohanbash, G., Okada, K., et al. (2015) Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation. Journal for ImmunoTherapy of Cancer, 3, P445. http://dx.doi.org/10.1186/2051-1426-3-S2-P445
|
[42]
|
Kohanbash, G., Okada, K., Liu, S., et al. (2016) Hg-81novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27m Mutation. Neuro-Oncology, 18, iii67.1-iii67.
|
[43]
|
Bloch, O., Crane, C.A., Fuks, Y., et al. (2014) Heat-Shock Protein Peptide Complex-96 Vaccination for Recurrent Glioblastoma: A Phase II, Single-Arm Trial. Neuro-Oncology, 16, 274-279. http://dx.doi.org/10.1093/neuonc/not203
|
[44]
|
Schumacher, T., Bunse, L., Pusch, S., et al. (2014) A Vaccine Targeting Mutant IDH1 Induces Antitumour Immunity. Nature, 512, 324-327. http://dx.doi.org/10.1038/nature13387
|
[45]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. http://dx.doi.org/10.1038/nrc3239
|
[46]
|
Wainwright, D.A., Chang, A.L., Dey, M., et al. (2014) Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors. Clinical Cancer Research, 20, 5290-5301.
http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
|
[47]
|
Weber, J.S., Yang, J.C., Atkins, M.B. and Disis, M.L. (2015) Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 33, 2092-2099.
http://dx.doi.org/10.1200/JCO.2014.60.0379
|
[48]
|
Ehtesham, M., Stevenson, C.B. and Thompson, R.C. (2005) Stem Cell Therapies for Malignant Glioma. Neurosurgical Focus, 19, E5. http://dx.doi.org/10.3171/foc.2005.19.3.6
|
[49]
|
Felgner, P.L., Gadek, T.R., Holm, M., et al. (1987) Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure. Proceedings of the National Academy of Sciences of the United States of America, 84, 7413-7417. http://dx.doi.org/10.1073/pnas.84.21.7413
|
[50]
|
Morris, L.G.T. and Chan, T.A. (2015) Therapeutic Targeting of Tumor Suppressor Genes: Therapeutic Targeting of Tumors. Cancer, 121, 1357-1368.
http://dx.doi.org/10.1002/cncr.29140
|
[51]
|
Abe, T., Terada, K., Wakimoto, H., et al. (2003) PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli. Cancer Research, 63, 2300-2305.
|
[52]
|
Chintala, S.K., Fueyo, J., Gomez-Manzano, C., et al. (1997) Adenovirus-Mediated p16/ CDKN2 Gene Transfer Suppresses Glioma Invasion in Vitro. Oncogene, 15, 2049-2057.
http://dx.doi.org/10.1038/sj.onc.1201382
|
[53]
|
Kim, S.-S., Rait, A., Kim, E., et al. (2015) A Tumor-Targeting p53 Nanodelivery System Limits Chemoresistance to Temozolomide Prolonging Survival in a Mouse Model of Glioblastoma Multiforme. Nanomedicine: Nanotechnology, Biology and Medicine, 11, 301-311.
http://dx.doi.org/10.1016/j.nano.2014.09.005
|
[54]
|
Lacy, P. and Stow, J.L. (2011) Cytokine Release from Innate Immune Cells: Association with Diverse Membrane Trafficking Pathways. Blood, 118, 9-18.
http://dx.doi.org/10.1182/blood-2010-08-265892
|
[55]
|
Tobias, A., Ahmed, A., Moon, K.-S. and Lesniak, M.S. (2013) The Art of Gene Therapy for Glioma: A Review of the Challenging Road to the Bedside. Journal of Neurology, Neurosurgery & Psychiatry, 84, 213-222. http://dx.doi.org/10.1136/jnnp-2012-302946
|
[56]
|
Chiocca, E.A., Smith, K.M., McKinney, B., et al. (2008) A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. Molecular Therapy, 16, 618-626.
http://dx.doi.org/10.1038/sj.mt.6300396
|
[57]
|
Yoshida, J., Mizuno, M., Fujii, M., et al. (2004) Human Gene Therapy for Malignant Gliomas (Glioblastoma Multiforme and Anaplastic Astrocytoma) by In Vivo Transduction with Human Interferon β Gene Using Cationic Liposomes. Human Gene Therapy, 15, 77-86. http://dx.doi.org/10.1089/10430340460732472
|
[58]
|
Duarte, S., Carle, G., Faneca, H., et al. (2012) Suicide Gene Therapy in Cancer: Where Do We Stand Now? Cancer Letters, 324, 160-170.
http://dx.doi.org/10.1016/j.canlet.2012.05.023
|
[59]
|
Beltinger, C., Fulda, S., Kammertoens, T., et al. (1999) Herpes Simplex Virus Thymidine Kinase/Ganciclovir-Induced Apoptosis Involves Ligand-Independent Death Receptor Aggregation and Activation of caspases. Proceedings of the National Academy of Sciences of the United States of America, 96, 8699-8704. http://dx.doi.org/10.1073/pnas.96.15.8699
|
[60]
|
Rainov, N.G. (2000) A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme. Human Gene Therapy, 11, 2389-2401. http://dx.doi.org/10.1089/104303400750038499
|
[61]
|
Colombo, F., Barzon, L., Franchin, E., et al. (2005) Combined HSV-TK/IL-2 Gene Therapy in Patients with Recurrent Glioblastoma Multiforme: Biological and Clinical Results. Cancer Gene Therapy, 12, 835-848. http://dx.doi.org/10.1038/sj.cgt.7700851
|
[62]
|
Okada, H., Giezeman-Smits, K.M., Tahara, H., et al. (1999) Effective Cytokine Gene Therapy against an Intracranial Glioma Using a Retrovirally Transduced IL-4 plus HSVtk Tumor Vaccine. Gene Therapy, 6, 219-226. http://dx.doi.org/10.1038/sj.gt.3300798
|
[63]
|
Okada, H., et al. (2000) Clinical Protocol: Gene Therapy of Malignant Gliomas: A Phase I Study of IL-4-HSV-TK Gene-Modified Autologous Tumor to Elicit an Immune Response. Human Gene Therapy, 11, 637-653. http://dx.doi.org/10.1089/10430340050015824
|
[64]
|
Perez, O.D., Logg, C.R., Hiraoka, K., et al. (2012) Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector with Improved Stability and Gene Expression. Molecular Therapy, 20, 1689-1698. http://dx.doi.org/10.1038/mt.2012.83
|
[65]
|
Lv, S.-Q., Zhang, K.-B., Zhang, E.E., et al. (2009) Antitumor Efficiency of the Cytosine Deaminase/5-Fluorocytosine Suicide Gene Therapy System on Malignant Gliomas: An in Vivo Study. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 15, BR13-BR20.
|
[66]
|
Chen, J.K., Hu, L.J., Wang, D., et al. (2007) Cytosine Deaminase/5-Fluorocytosine Exposure Induces Bystander and Radiosensitization Effects in Hypoxic Glioblastoma Cells in Vitro. nternational Journal of Radiation Oncology Biology Physics, 67, 1538-1547.
http://dx.doi.org/10.1016/j.ijrobp.2006.12.020
|
[67]
|
Miller, C.R., Williams, C.R., Buchsbaum, D.J. and Gillespie, G.Y. (2002) Intratumoral 5-Fluorouracil Produced by Cytosine Deaminase/5-Fluorocytosine Gene Therapy Is Effective for Experimental Human Glioblastomas. Cancer Research, 62, 773-780.
|
[68]
|
Cloughesy, T.F., Landolfi, J., Hogan, D.J., et al. (2016) Phase 1 Trial of Vocimagene Amiretrorepvec and 5-Fluorocytosine for Recurrent High-Grade Glioma. Science Translational Medicine, 8, 341ra75-341ra75.
|
[69]
|
Kwiatkowska, A., Nandhu, M., Behera, P., et al. (2013) Strategies in Gene Therapy for Glioblastoma. Cancers, 5, 1271-1305. http://dx.doi.org/10.3390/cancers5041271
|
[70]
|
Aghi, M., Visted, T., DePinho, R.A. and Chiocca, E.A. (2008) Oncolytic Herpes Virus with Defective ICP6 Specifically Replicates in Quiescent Cells with Homozygous Genetic Mutations in p16. Oncogene, 27, 4249-4254. http://dx.doi.org/10.1038/onc.2008.53
|
[71]
|
Markert, J.M., Razdan, S.N., Kuo, H.-C., et al. (2014) A Phase I Trial of Oncolytic HSV-1, G207, Given in Combination with Radiation for Recurrent GBM demonstrates Safety and Radiographic Responses. Molecular Therapy, 22, 1048-1055.
|
[72]
|
Whisenhunt, T.R., Rajneesh, K.F., Hackney, J.R. and Markert, J.M. (2015) Extended Disease-Free Interval of 6 Years in a Recurrent Glioblastoma Multiforme Patient Treated with G207 Oncolytic Viral Therapy. Oncolytic Virotherapy, 4, 33-38.
|
[73]
|
Chinot, O.L., Wick, W., Mason, W., et al. (2014) Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. The New England Journal of Medicine, 370, 709-722. http://dx.doi.org/10.1056/NEJMoa1308345
|
[74]
|
Wick, W., Brandes, A., Gorlia, T., et al. (2015) Lb-05phase Iii Trial Exploring the Combination of Bevacizumab and Lomustine in Patients with First Recurrence of a Glioblastoma: The Eortc 26101 Trial. Neuro-Oncology, 17, v1.5-v1.
|
[75]
|
Batchelor, T.T., Mulholland, P., Neyns, B., et al. (2013) Phase III Randomized Trial Comparing the Efficacy of Cediranib as Monotherapy, and in Combination with Lomustine, versus Lomustine Alone in Patients with Recurrent Glioblastoma. Journal of Clinical Oncology, 31, 3212-3218. http://dx.doi.org/10.1200/JCO.2012.47.2464
|
[76]
|
Spence, R.R., Heesch, K.C. and Brown, W.J. (2010) Exercise and Cancer Rehabilitation: A Systematic Review. Cancer Treatment Reviews, 36, 185-194.
http://dx.doi.org/10.1016/j.ctrv.2009.11.003
|
[77]
|
Okamura, H. (2011) Importance of Rehabilitation in Cancer Treatment and Palliative Medicine. Japanese Journal of Clinical Oncology, 41, 733-738.
http://dx.doi.org/10.1093/jjco/hyr061
|
[78]
|
Dietz, J.H. (1969) Rehabilitation of the Cancer Patient. Medical Clinics of North America, 53, 607-624.
|
[79]
|
Gillis, T.A., Yadav, R. and Guo, Y. (2002) Rehabilitation of Patients with Neurologic Tumors and Cancer-Related Central Nervous System Disabilities. 2nd Edition, Oxford University Press, New York, 341-361.
|
[80]
|
Ruden, E., Reardon, D.A., Coan, A.D., et al. (2011) Exercise Behavior, Functional Capacity, and Survival in Adults with Malignant Recurrent Glioma. Journal of Clinical Oncology, 29, 2918-2923. http://dx.doi.org/10.1200/JCO.2011.34.9852
|
[81]
|
Ainsworth, B.E., Haskell, W.L., Whitt, M.C., et al. (2000) Compendium of Physical Activities: an Update of Activity Codes and MET Intensities. Medicine & Science in Sports & Exercise, 32, S498-S504. http://dx.doi.org/10.1097/00005768-200009001-00009
|
[82]
|
Thompson, H.J., Wolfe, P., McTiernan, A., et al. (2010) Wheel Running-Induced Changes in Plasma Biomarkers and Carcinogenic Response in the 1-Methyl-1-Nitrosourea-Induced Rat Model for Breast Cancer. Cancer Prevention Research, 3, 1484-1492.
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0078
|
[83]
|
Miller, J.D. and Leech, P. (1975) Effects of Mannitol and Steroid Therapy on Intracranial Volume-Pressure Relationships in Patients. Journal of Neurosurgery, 42, 274-281.
http://dx.doi.org/10.3171/jns.1975.42.3.0274
|
[84]
|
Miller, J.D., Sakalas, R., Ward, J.D., et al. (1977) Methylprednisolone Treatment in Patients with Brain Tumors. Neurosurgery, 1, 114-117.
http://dx.doi.org/10.1227/00006123-197709000-00005
|
[85]
|
Yeung, W.T., Lee, T.Y., Del Maestro, R.F., et al. (1994) Effect of Steroids on Iopamidol Blood-Brain Transfer Constant and Plasma Volume in Brain Tumors Measured with X-Ray Computed Tomography. Journal of Neurosurgery, 18, 53-60.
http://dx.doi.org/10.1007/BF01324604
|
[86]
|
Markman, M., Sheidler, V., Ettinger, D.S., et al. (1984) Antiemetic Efficacy of Dexamethasone. The New England Journal of Medicine, 311, 549-552.
http://dx.doi.org/10.1056/NEJM198408303110901
|
[87]
|
Ingraham, F.D., Matson, D.D. and McLaurin, R.L. (1952) Cortisone and ACTH as an Adjunct to the Surgery of Craniopharyngiomas. The New England Journal of Medicine, 246, 568-571. http://dx.doi.org/10.1056/NEJM195204102461502
|
[88]
|
French, L.A. and Galicich, J.H. (1964) The Use of Steroids for Control of Cerebral Edema. Clinical Neurosurgery, 10, 212-223.
|
[89]
|
Bell, B.A., Smith, M.A., Kean, D.M., et al. (1987) Brain Water Measured by Magnetic Resonance Imaging. Correlation with Direct Estimation and Changes after Mannitol and Dexamethasone. Lancet, 1, 66-69. http://dx.doi.org/10.1016/S0140-6736(87)91908-8
|
[90]
|
Ryken, T.C., McDermott, M., Robinson, P.D., et al. (2010) The Role of Steroids in the Management of Brain Metastases: A Systematic Review and Evidence-Based Clinical Practice Guideline. Journal of Neurosurgery, 96, 103-114.
http://dx.doi.org/10.1007/s11060-009-0057-4
|
[91]
|
Cross, K.P., Paul, R.I. and Goldman, R.D. (2011) Single-Dose Dexamethasone for Mild-to-Moderate Asthma Exacerbations Effective, Easy, and Acceptable. Canadian Family Physician, 57, 1134-1136.
|
[92]
|
Vecht, C.J., Hovestadt, A., Verbiest, H.B.C., et al. (1994) Dose-Effect Relationship of Dexamethasone on Karnofsky Performance in Metastatic Brain Tumors: A Randomized Study of Doses of 4, 8, and 16 mg per Day. Neurology, 44, 675-675.
http://dx.doi.org/10.1212/WNL.44.4.675
|
[93]
|
Marantidou, A., Levy, C., Duquesne, A., et al. (2010) Steroid Requirements during Radiotherapy for Malignant Gliomas. Journal of Neurosurgery, 100, 89-94.
http://dx.doi.org/10.1007/s11060-010-0142-8
|
[94]
|
Barnes, P.J. (2005) Molecular Mechanisms and Cellular Effects of Glucocorticosteroids. Immunology and Allergy Clinics of North America, 25, 451-468.
http://dx.doi.org/10.1016/j.iac.2005.05.003
|
[95]
|
Cifone, M.G., Migliorati, G., Parroni, R., et al. (1999) Dexamethasone-Induced Thymocyte Apoptosis: Apoptotic Signal Involves the Sequential Activation of Phosphoinositide-Specific Phospholipase C, Acidic Sphingomyelinase, and Caspases. Blood, 93, 2282-2296.
|
[96]
|
Winkler, E.A., Bell, R.D. and Zlokovic, B.V. (2011) Central Nervous System Pericytes in Health and Disease. Nature Neuroscience, 14, 1398-1405.
http://dx.doi.org/10.1038/nn.2946
|
[97]
|
Abbott, N.J., Ronnback, L. and Hansson, E. (2006) Astrocyte-Endothelial Interactions at the Blood-Brain Barrier. Nature Reviews Neuroscience, 7, 41-53.
http://dx.doi.org/10.1038/nrn1824
|
[98]
|
Machein, M.R. and Plate, K.H. (2000) VEGF in Brain Tumors. Journal of Neurosurgery, 50, 109-120. http://dx.doi.org/10.1023/A:1006416003964
|
[99]
|
Wen, P., Schiff, D., Kesari, S., et al. (2006) Medical Management of Patients with Brain Tumors. Journal of Neurosurgery, 80, 313-332.
http://dx.doi.org/10.1007/s11060-006-9193-2
|
[100]
|
Papadopoulos, M.C., Saadoun, S., Binder, D.K., et al. (2004) Molecular Mechanisms of Brain Tumor Edema. Neuroscience, 129, 1011-1020.
http://dx.doi.org/10.1016/j.neuroscience.2004.05.044
|
[101]
|
Hedley-Whyte, E.T. and Hsu, D.W. (1986) Effect of Dexamethasone on Blood-Brain Barrier in the Normal Mouse. Annals of Neurology, 19, 373-377.
http://dx.doi.org/10.1002/ana.410190411
|
[102]
|
Forster, C., Silwedel, C., Golenhofen, N., et al. (2005) Occludin as Direct Target for Glucocorticoid-Induced Improvement of Blood-Brain Barrier Properties in a Murine in Vitro System. The Journal of Physiology, 565, 475-486.
http://dx.doi.org/10.1113/jphysiol.2005.084038
|
[103]
|
Koehler, P.J. (1995) Use of Corticosteroids in Neuro-Oncology. Anticancer Drugs, 6, 19-33.
http://dx.doi.org/10.1097/00001813-199502000-00002
|
[104]
|
Deutsch, M.B., Panageas, K.S., Lassman, A.B. and DeAngelis, L.M. (2013) Steroid Management in Newly Diagnosed Glioblastoma. Journal of Neurosurgery, 113, 111-116.
http://dx.doi.org/10.1007/s11060-013-1096-4
|
[105]
|
Das, A., Banik, N.L., Patel, S.J. and Ray, S.K. (2004) Dexamethasone Protected Human Glioblastoma U87MG Cells from Temozolomide Induced Apoptosis by Maintaining Bax: Bcl-2 Ratio and Preventing Proteolytic Activities. Molecular Cancer, 3, 36.
http://dx.doi.org/10.1186/1476-4598-3-36
|
[106]
|
Rosati, A., Buttolo, L., Stefini, R., et al. (2010) Efficacy and Safety of Levetiracetam in Patients with Glioma: A Clinical Prospective Study. Archives of Neurology, 2009, 335.
http://dx.doi.org/10.1001/archneurol.2009.335
|
[107]
|
Sepkowitz, K.A., Brown, A.E., Telzak, E.E., et al. (1992) Pneumocystis Carinii Pneumonia among Patients without AIDS at a Cancer Hospital. JAMA, 267, 832-837.
http://dx.doi.org/10.1001/jama.1992.03480060078034
|
[108]
|
Schiff, D. (1996) Pneumocystis Pneumonia in Brain Tumor Patients: Risk Factors and Clinical Features. Journal of Neurosurgery, 27, 235-240.
http://dx.doi.org/10.1007/BF00165480
|
[109]
|
Gundersen, S., Lote, K. and Hannisdal, E. (1996) Prognostic Factors for Glioblastoma Multiforme-Development of a Prognostic Index. Acta Oncologica (Stockholm, Sweden), 35 123-127. http://dx.doi.org/10.3109/02841869609098530
|
[110]
|
Watne, K., Hannisdal, E., Nome, O., et al. (1993) Prognostic Factors in Malignant Gliomas with Special Reference to Intra-Arterial Chemotherapy. Acta Oncologica (Stockholm, Sweden), 32, 307-310. http://dx.doi.org/10.3109/02841869309093600
|
[111]
|
Kaal, E.C. and Vecht, C.J. (2004) The Management of Brain Edema in Brain Tumors. Current Opinion in Oncology, 16, 593-600.
http://dx.doi.org/10.1097/01.cco.0000142076.52721.b3
|
[112]
|
Amatruda, T.T., Hurst, M.M. and D’Esopo, N.D. (1965) Certain Endocrine and Metabolic Facets of the Steroid Withdrawal Syndrome. Journal of Clinical Endocrinology & Metabolism, 25, 1207-1217. http://dx.doi.org/10.1210/jcem-25-9-1207
|
[113]
|
Gilbert, M.R., Dignam, J.J., Armstrong, T.S., et al. (2014) A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. The New England Journal of Medicine, 370, 699-708. http://dx.doi.org/10.1056/NEJMoa1308573
|
[114]
|
Peak, S.J. and Levin, V.A. (2010) Role of Bevacizumab Therapy in the Management of Glioblastoma. Journal of Cancer Management and Research, 2, 97.
|
[115]
|
Portnow, J., Suleman, S., Grossman, S.A., et al. (2002) A Cyclooxygenase-2 (COX-2) Inhibitor Compared with Dexamethasone in a Survival Study of Rats with Intracerebral 9L Gliosarcomas. Neuro-Oncoogylogy, 4, 22-25. http://dx.doi.org/10.1215/15228517-4-1-22
|
[116]
|
Nathoo, N., Barnett, G.H. and Golubic, M. (2004) The Eicosanoid Cascade: Possible Role in Gliomas and Meningiomas. Journal of Clinical Pathology, 57, 6-13.
http://dx.doi.org/10.1136/jcp.57.1.6
|
[117]
|
Tjuvajev, J., Uehara, H., Desai, R., et al. (1996) Corticotropin-Releasing Factor Decreases Vasogenic Brain Edema. Cancer Research, 56, 1352-1360.
|
[118]
|
Villalona-Calero, M.A., Eckardt, J., Burris, H., et al. (1998) A Phase I Trial of Human Corticotropin-Releasing Factor (hCRF) in Patients with Peritumoral Brain Edema. Annals of Oncology, 9, 71-77. http://dx.doi.org/10.1023/A:1008251426425
|
[119]
|
Hauser, W.A., Annegers, J.F. and Kurland, L.T. (1993) Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935-1984. Epilepsia, 34, 453-458.
http://dx.doi.org/10.1111/j.1528-1157.1993.tb02586.x
|
[120]
|
Herman, S.T. (2002) Epilepsy after Brain Insult: Targeting Epileptogenesis. Neurology, 59, S21-S26. http://dx.doi.org/10.1212/WNL.59.9_suppl_5.S21
|
[121]
|
Glantz, M.J., Cole, B.F., Forsyth, P.A., et al. (2000) Practice Parameter: Anticonvulsant Prophylaxis in Patients with Newly Diagnosed Brain Tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 54, 1886-1893.
http://dx.doi.org/10.1212/WNL.54.10.1886
|
[122]
|
Fonkem, E., Bricker, P., Mungall, D., et al. (2013) The Role of Levetiracetam in Treatment of Seizures in Brain Tumor Patients. Frontiers in Neurology, 4, 153.
http://dx.doi.org/10.3389/fneur.2013.00153
|
[123]
|
Temkin, N.R. (2002) Prophylactic Anticonvulsants after Neurosurgery. Epilepsy Currents, 2, 105-107. http://dx.doi.org/10.1046/j.1535-7597.2002.00038.x
|
[124]
|
Yang, X.-F., Weisenfeld, A. and Rothman, S.M. (2007) Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission. Epilepsia, 48, 1861-1869.
http://dx.doi.org/10.1111/j.1528-1167.2006.01132.x
|
[125]
|
Cramer, J.A., De Rue, K., Devinsky, O., et al. (2003) A Systematic Review of the Behavioral Effects of Levetiracetam in Adults with Epilepsy, Cognitive Disorders, or an Anxiety Disorder during Clinical Trials. Epilepsy & Behavior, 4, 124-132.
http://dx.doi.org/10.1016/S1525-5050(03)00005-2
|
[126]
|
Coppola, G., Mangano, S., Tortorella, G., et al. (2004) Levetiracetam during 1-Year Follow-Up in Children, Adolescents, and Young Adults with Refractory Epilepsy. Epilepsy Research, 59, 35-42. http://dx.doi.org/10.1016/j.eplepsyres.2004.03.006
|
[127]
|
Dinkelacker, V., Dietl, T., Widman, G., et al. (2003) Aggressive Behavior of Epilepsy Patients in the Course of Levetiracetam Add-On Therapy: Report of 33 Mild to Severe Cases. Epilepsy & Behavior, 4, 537-547. http://dx.doi.org/10.1016/j.yebeh.2003.07.008
|
[128]
|
Major, P., Greenberg, E., Khan, A. and Thiele, E.A. (2008) Pyridoxine Supplementation for the Treatment of Levetiracetam-Induced Behavior Side Effects in Children: Preliminary Results. Epilepsy & Behavior, 13, 557-559. http://dx.doi.org/10.1016/j.yebeh.2008.07.004
|
[129]
|
Bobustuc, G.C., Baker, C.H., Limaye, A., et al. (2010) Levetiracetam Enhances p53-mediated MGMT Inhibition and Sensitizes Glioblastoma Cells to Temozolomide. Neuro-Oncology, 12, 917-927. http://dx.doi.org/10.1093/neuonc/noq044
|
[130]
|
Kuo, C.-C. (1998) A Common Anticonvulsant Binding Site for Phenytoin, Carbamazepine, and Lamotrigine in Neuronal Na+ Channels. Molecular Pharmacology, 54, 712-721.
|
[131]
|
Ruegg, S. (2002) Dexamethasone/Phenytoin Interactions: Neurooncological Concerns. Swiss Medical Weekly, 132, 425-426.
|
[132]
|
Chalk, J.B., Ridgeway, K., Brophy, T., et al. (1984) Phenytoin Impairs the Bioavailability of Dexamethasone in Neurological and Neurosurgical Patients. Journal of Neurology, Neurosurgery & Psychiatry, 47, 1087-1090. http://dx.doi.org/10.1136/jnnp.47.10.1087
|
[133]
|
Choi, Y., Thrasher, K., Werk, E.E., et al. (1971) Effect of Diphenylhydantoin on Cortisol Kinetics in Humans. Journal of Pharmacology and Experimental Therapeutics, 176, 27-34.
|
[134]
|
Postmarket Drug Safety Information for Patients and Providers > Suicidal Behavior and Ideation and Antiepileptic Drugs.
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders /UCM100190
|
[135]
|
Mula, M., Kanner, A.M., Schmitz, B. and Schachter, S. (2013) Antiepileptic Drugs and Suicidality: An Expert Consensus Statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology: Antiepileptic Drugs and Suicidality. Epilepsia, 54, 199-203. http://dx.doi.org/10.1111/j.1528-1167.2012.03688.x
|
[136]
|
Wallace, J.L. (2000) How Do NSAIDs Cause Ulcer Disease? Baillières Best Practice & Research Clinical Gastroenterology, 14, 147-159. http://dx.doi.org/10.1053/bega.1999.0065
|
[137]
|
Weissman, D., Dufer, D., Vogel, V. and Abeloff, M. (1987) Corticosteroid Toxicity in Neuro-Oncology Patients. Journal of Neuro-Oncology, 5, 125-128.
http://dx.doi.org/10.1007/BF02571300
|
[138]
|
Conn, H.O. and Poynard, T. (1994) Corticosteroids and Peptic Ulcer: Meta-Analysis of Adverse Events during Steroid Therapy. Journal of Internal Medicine, 236, 619-632.
http://dx.doi.org/10.1111/j.1365-2796.1994.tb00855.x
|
[139]
|
Carson, J.L., Strom, B.L., Schinnar, R., et al. (1991) The Low Risk of Upper Gastrointestinal Bleeding in Patients Dispensed Corticosteroids. American Journal of Medicine, 91, 223-228. http://dx.doi.org/10.1016/0002-9343(91)90119-I
|
[140]
|
Conn, H.O. and Poynard, T. (1985) Adrenocorticosteroid Administration and Peptic Ulcer: A Critical Analysis. Journal of Chronic Diseases, 38, 457-468.
http://dx.doi.org/10.1016/0021-9681(85)90028-1
|
[141]
|
Barada, K., Abdul-Baki, H., El Hajj, II, et al. (2009) Gastrointestinal Bleeding in the Setting of Anticoagulation and Antiplatelet Therapy. Journal of Clinical Gastroenterology, 43, 5-12.
http://dx.doi.org/10.1097/MCG.0b013e31811edd13
|
[142]
|
Ballinger, A. and Smith, G. (2001) COX-2 Inhibitors vs. NSAIDs in Gastrointestinal Damage and Prevention. Expert Opinion on Pharmacotherapy, 2, 31-40.
http://dx.doi.org/10.1517/14656566.2.1.31
|
[143]
|
Lindley, C.M., Hirsch, J.D., O’Neill, C.V., et al. (1992) Quality of Life Consequences of Chemotherapy-Induced Emesis. Quality of Life Research, 1, 331-340.
http://dx.doi.org/10.1007/BF00434947
|
[144]
|
Bloechl-Daum, B. (2006) Delayed Nausea and Vomiting Continue to Reduce Patients’ Quality of Life after Highly and Moderately Emetogenic Chemotherapy despite Antiemetic Treatment. Journal of Clinical Oncology, 24, 4472-4478.
http://dx.doi.org/10.1200/JCO.2006.05.6382
|
[145]
|
Hesketh, P.J. (2008) Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine, 358, 2482-2494. http://dx.doi.org/10.1056/NEJMra0706547
|
[146]
|
Tramèr, M.R., Carroll, D., Campbell, F.A., et al. (2001) Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systematic Review. BMJ, 323, 16.
http://dx.doi.org/10.1136/bmj.323.7303.16
|
[147]
|
Sutton, I.R. and Daeninck, P. (2006) Cannabinoids in the Management of Intractable Chemotherapy-Induced Nausea and Vomiting and Cancer-Related Pain. The Journal of Supportive Oncology, 4, 531-535.
|
[148]
|
Aapro, M.S. and Alberts, D.S. (1981) High-Dose Dexamethasone for Prevention of Cis-Platin-Induced Vomiting. Cancer Chemotherapy and Pharmacology, 7, 11-14.
http://dx.doi.org/10.1007/BF00258206
|
[149]
|
Cassileth, P.A. (1983) Antiemetic Efficacy of Dexamethasone Therapy in Patients Receiving Cancer Chemotherapy. Archives of Internal Medicine, 143, 1347.
http://dx.doi.org/10.1001/archinte.1983.00350070063012
|
[150]
|
Hesketh, P.J., Harvey, W.H., Harker, W.G., et al. (1994) A Randomized, Double-Blind Comparison of Intravenous Ondansetron Alone and in Combination with Intravenous Dexamethasone in the Prevention of High-Dose Cisplatin-Induced Emesis. Journal of Clinical Oncology, 12, 596-600.
|
[151]
|
Latreille, J., Stewart, D., Laberge, F., et al. (1995) Dexamethasone Improves the Efficacy of Granisetron in the First 24 h Following High-Dose Cisplatin Chemotherapy. Support Care Cancer, 3, 307-312.
|
[152]
|
Loprinzi, C.L., Kugler, J.W., Sloan, J.A., et al. (1999) Randomized Comparison of Megestrol Acetate versus Dexamethasone versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia. Journal of Clinical Oncology, 17, 3299-3306.
|
[153]
|
Ness-Abramof, R. and Apovian, C.M. (2005) Drug-Induced Weight Gain. Timely Top Med Cardiovasc Dis, 9, E31. http://dx.doi.org/10.1358/dot.2005.41.8.893630
|
[154]
|
Thompson, D., Takeshita, J., Thompson, T. and Mulligan, M. (2006) Selecting Antiepileptic Drugs for Symptomatic Patients with Brain Tumors. The Journal of Supportive Oncology, 4, 411-416.
|
[155]
|
Berry, E.M. and Mechoulam, R. (2002) Tetrahydrocannabinol and Endocannabinoids in Feeding and Appetite. Pharmacology & Therapeutics, 95, 185-190.
http://dx.doi.org/10.1016/S0163-7258(02)00257-7
|
[156]
|
Dropcho, E.J. and Soong, S.J. (1991) Steroid-Induced Weakness in Patients with Primary Brain tumors. Neurology, 41, 1235-1239. http://dx.doi.org/10.1212/WNL.41.8.1235
|
[157]
|
Vick, N.A. (1988) Steroid Toxicity. Journal of Neuro-Oncology, 6, 199.
http://dx.doi.org/10.1007/BF02327397
|
[158]
|
Gupta, Y. and Gupta, A. (2013) Glucocorticoid-Induced Myopathy: Pathophysiology, Diagnosis, and Treatment. Indian Journal of Endocrinology and Metabolism, 17, 913.
http://dx.doi.org/10.4103/2230-8210.117215
|
[159]
|
La Pier, T.K. (1997) Glucocorticoid-Induced Muscle Atrophy. The Role of Exercise in Treatment and Prevention. Journal of Cardiopulmonary Rehabilitation and Prevention, 17, 76-84. http://dx.doi.org/10.1097/00008483-199703000-00002
|
[160]
|
Braith, R.W., Welsch, M.A., Mills, R.M., et al. (1998) Resistance Exercise Prevents Glucocorticoid-Induced Myopathy in Heart Transplant Recipients. Medicine & Science in Sports & Exercise, 30, 483-489. http://dx.doi.org/10.1097/00005768-199804000-00003
|
[161]
|
Kelly, F.J., McGrath, J.A., Goldspink, D.F. and Cullen, M.J. (1986) A Morphological/Biochemical Study on the Actions of Corticosteroids on Rat Skeletal Muscle. Muscle Nerve, 9, 1-10. http://dx.doi.org/10.1002/mus.880090102
|
[162]
|
Koski, C.L., Rifenberick, D.H. and Max, S.R. (1974) Oxidative Metabolism of Skeletal Muscle in Steroid Atrophy. Archives of Neurology, 31, 407-410.
http://dx.doi.org/10.1001/archneur.1974.00490420073008
|
[163]
|
Kovacs, J.A. and Masur, H. (2000) Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. The New England Journal of Medicine, 342, 1416-1429. http://dx.doi.org/10.1056/NEJM200005113421907
|
[164]
|
Festic, E., Gajic, O., Limper, A.H. and Aksamit, T.R. (2005) Acute Respiratory Failure due to Pneumocystis Pneumonia in Patients without Human Immunodeficiency Virus Infection Outcome and Associated Features. Chest, 128, 573-579.
http://dx.doi.org/10.1378/chest.128.2.573
|
[165]
|
Hardy, W.D., Feinberg, J., Finkelstein, D.M., et al. (1992) A Controlled Trial of Trimethoprim-Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. AIDS Clinical Trials Group Protocol 021. The New England Journal of Medicine, 327, 1842-1848. http://dx.doi.org/10.1056/NEJM199212243272604
|
[166]
|
Schneider, M.M., Hoepelman, A.I., Eeftinck Schattenkerk, J.K., et al. (1992) A Controlled Trial of Aerosolized Pentamidine or Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis Carinii Pneumonia in Patients with Human Immunodeficiency Virus Infection. The Dutch AIDS Treatment Group. The New England Journal of Medicine, 327, 1836-1841. http://dx.doi.org/10.1056/NEJM199212243272603
|
[167]
|
Woo SLK, S.C., Amiel, D., Gomez, M.A., Hayes, W.C., White, F.C. and Akeson, W.H. (1981) The Effect of Prolonged Physical Training on the Properties of Long Bone: A Study of Wolff’s Law. Journal of Bone and Joint Surgery, 63, 780-787.
|
[168]
|
Popp, A.W., Isenegger, J., Buergi, E.M., et al. (2006) Glucocorticosteroid-Induced Spinal Osteoporosis: Scientific Update on Pathophysiology and Treatment. European Spine Journal, 15, 1035-1049. http://dx.doi.org/10.1007/s00586-005-0056-x
|
[169]
|
Grossman, J.M., Gordon, R., Ranganath, V.K., et al. (2010) American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care & Research, 62, 1515-1526.
http://dx.doi.org/10.1002/acr.20295
|
[170]
|
Litofsky, N.S. and Resnick, A.G. (2009) The Relationships between Depression and Brain Tumors. Journal of Neuro-Oncology, 94, 153-161.
http://dx.doi.org/10.1007/s11060-009-9825-4
|
[171]
|
Weitzner, M.A. and Meyers, C.A. (1997) Cognitive Functioning and Quality of Life in Malignant Glioma Patients: A Review of the Literature. Psychooncology, 6, 169-177.
http://dx.doi.org/10.1002/(SICI)1099-1611(199709)6:3<169::AID-PON269>3.0.CO;2-#
|
[172]
|
Crossen, J.R., Garwood, D., Glatstein, E. and Neuwelt, E.A. (1994) Neurobehavioral Sequelae of Cranial Irradiation in Adults: A Review of Radiation-Induced Encephalopathy. Journal of Clinical Oncology, 12, 627-642.
|
[173]
|
Pelletier, G., Verhoef, M.J., Khatri, N. and Hagen, N. (2002) Quality of Life in Brain Tumor Patients: The Relative Contributions of Depression, Fatigue, Emotional Distress, and Existential Issues. Journal of Neuro-Oncology, 57, 41-49.
http://dx.doi.org/10.1023/A:1015728825642
|
[174]
|
Truhan, A.P. and Ahmed, A.R. (1989) Corticosteroids: A Review with Emphasis on Complications of Prolonged Systemic Therapy. Annals of Allergy, 62, 375-391.
|
[175]
|
Bosma, I., Vos, M.J., Heimans, J.J., et al. (2007) The Course of Neurocognitive Functioning in High-Grade Glioma Patients. Journal of Neuro-Oncology, 9, 53-62.
http://dx.doi.org/10.1215/15228517-2006-012
|
[176]
|
Klein, M., Postma, T.J., Taphoorn, M.J.B., et al. (2003) The Prognostic Value of Cognitive Functioning in the Survival of Patients with High-Grade Glioma. Neurology, 61, 1796-1798. http://dx.doi.org/10.1212/01.WNL.0000098892.33018.4C
|
[177]
|
Meyers, C.A., Hess, K.R., Yung, W.A. and Levin, V.A. (2000) Cognitive Function as a Predictor of Survival in Patients with Recurrent Malignant Glioma. Journal of Clinical Oncology, 18, 646.
|
[178]
|
Gehring, K., Sitskoorn, M.M., Gundy, C.M., et al. (2009) Cognitive Rehabilitation in Patients with Gliomas: A Randomized, Controlled Trial. Journal of Clinical Oncology, 27, 3712-3722. http://dx.doi.org/10.1200/JCO.2008.20.5765
|
[179]
|
Klein, M., Taphoorn, M.J., Heimans, J.J., et al. (2001) Neurobehavioral Status and Health-Related Quality of Life in Newly Diagnosed High-Grade Glioma Patients. Journal of Clinical Oncology, 19, 4037-4047.
|
[180]
|
Gehring, K., Aaronson, N.K., Gundy, C.M., et al. (2011) Predictors of Neuropsychological Improvement Following Cognitive Rehabilitation in Patients with Gliomas. Journal of the International Neuropsychological Society, 17, 256-266.
http://dx.doi.org/10.1017/S1355617710001530
|
[181]
|
Katzman, R., Terry, R., De Teresa, R., et al. (1988) Clinical, Pathological, and Neurochemical Changes in Dementia: A Subgroup with Preserved Mental Status and Numerous Neocortical Plaques. Annals of Neurology, 23, 138-144.
http://dx.doi.org/10.1002/ana.410230206
|
[182]
|
Stern, Y. (2002) What Is Cognitive Reserve? Theory and Research Application of the Reserve Concept. Journal of the International Neuropsychological Society, 8, 448-460.
http://dx.doi.org/10.1017/S1355617702813248
|
[183]
|
Mainio, A., Tuunanen, S., Hakko, H., et al. (2006) Decreased Quality of Life and Depression as Predictors for Shorter Survival among Patients with Low-Grade Gliomas: A Follow-Up from 1990 to 2003. European Archives of Psychiatry and Clinical Neuroscience, 256, 516-521. http://dx.doi.org/10.1007/s00406-006-0674-2
|
[184]
|
Armstrong, C., Goldstein, B., Cohen, B., et al. (2002) Clinical Predictors of Depression in Patients with Low-Grade Brain Tumors: Consideration of a Neurologic Versus a Psychogenic Model. J Journal of Clinical Psychology in Medical Settings, 9, 97-107.
http://dx.doi.org/10.1023/A:1014987925718
|
[185]
|
Litofsky, N.S., Farace, E., Anderson, F., et al. (2004) Depression in Patients with High-Grade Glioma: Results of the Glioma Outcomes Project. Neurosurgery, 54, 358-367.
http://dx.doi.org/10.1227/01.neu.0000103450.94724.a2
|
[186]
|
Cassano, P. and Fava, M. (2004) Tolerability Issues during Long-Term Treatment with Antidepressants. Annals of Clinical Psychiatry, 16, 15-25.
http://dx.doi.org/10.1080/10401230490281618
|
[187]
|
Peretti, S., Judge, R. and Hindmarch, I. (2000) Safety and Tolerability Considerations: Tricyclic Antidepressants vs. Selective Serotonin Reuptake Inhibitors. Acta Psychiatrica Scandinavica, 403, 17-25. http://dx.doi.org/10.1111/j.1600-0447.2000.tb10944.x
|
[188]
|
Montgomery, S.A. (2005) Antidepressants and Seizures: Emphasis on Newer Agents and Clinical Implications. International Journal of Clinical Practice, 59, 1435-1440.
http://dx.doi.org/10.1111/j.1368-5031.2005.00731.x
|
[189]
|
Hachad, H., Ragueneau-Majlessi, I. and Levy, R.H. (2002) New Antiepileptic Drugs: Review on Drug Interactions. Therapeutic Drug Monitoring, 24, 91-103.
http://dx.doi.org/10.1097/00007691-200202000-00016
|
[190]
|
Gajwani, P., Forsthoff, A., Muzina, D., et al. (2005) Antiepileptic Drugs in Mood-Disordered Patients. Epilepsia, 46, 38-44. http://dx.doi.org/10.1111/j.1528-1167.2005.463008.x
|
[191]
|
Mattes, J.A. (2005) Oxcarbazepine in Patients with Impulsive Aggression: A Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychopharmacology, 25, 575-579.
http://dx.doi.org/10.1097/01.jcp.0000186739.22395.6b
|
[192]
|
Rickels, K., Pollack, M.H., Feltner, D.E., et al. (2005) Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-Blind, Placebo-Controlled Trial of Pregabalin and Alprazolam. Archives of General Psychiatry, 62, 1022-1030.
http://dx.doi.org/10.1001/archpsyc.62.9.1022
|
[193]
|
Simon, N.M., Worthington, J.J., Doyle, A.C., et al. (2004) An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder. Journal of Clinical Psychiatry, 65, 1219-1222. http://dx.doi.org/10.4088/JCP.v65n0909
|
[194]
|
Kinrys, G., Worthington, J.J., Wygant, L., et al. (2007) Levetiracetam as Adjunctive Therapy for Refractory Anxiety Disorders. Journal of Clinical Psychiatry, 68, 1010-1013.
http://dx.doi.org/10.4088/JCP.v68n0705
|
[195]
|
Rosenthal, M. (2003) Tiagabine for the Treatment of Generalized Anxiety Disorder: A Randomized, Open-Label, Clinical Trial with Paroxetine as a Positive Control. Journal of Clinical Psychiatry, 64, 1245-1249. http://dx.doi.org/10.4088/JCP.v64n1016
|
[196]
|
Dimeo, F.C., Stieglitz, R.-D., Novelli-Fischer, U., et al. (1999) Effects of Physical Activity on the Fatigue and Psychologic Status of Cancer Patients during Chemotherapy. Cancer, 85, 2273-2277.
http://dx.doi.org/10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B
|
[197]
|
Meyers, C.A., Weitzner, M.A., Valentine, A.D. and Levin, V.A. (1998) Methylphenidate Therapy Improves Cognition, Mood, and Function of Brain Tumor Patients. Journal of Clinical Oncology, 16, 2522-2527.
|
[198]
|
Erman, M.K. and Rosenberg, R., Modafinil Shift Work Sleep Disorder Study Group (2007) Modafinil for Excessive Sleepiness Associated with Chronic Shift Work Sleep Disorder: Effects on Patient Functioning and Health-Related Quality of Life. The Primary Care Companion: Journal of Clinical Psychiatry, 9, 188-194. http://dx.doi.org/10.4088/PCC.v09n0304
|
[199]
|
Boele, F.W., Douw, L., de Groot, M., et al. (2013) The Effect of Modafinil on Fatigue, Cognitive Functioning, and Mood in Primary Brain Tumor Patients: A Multicenter Randomized Controlled Trial. Journal of Neuro-Oncology, 15, 1420-1428.
http://dx.doi.org/10.1093/neuonc/not102
|
[200]
|
Barton, D.L., Liu, H., Dakhil, S.R., et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2. Journal of the National Cancer Institute, 105, 1230-1238. http://dx.doi.org/10.1093/jnci/djt181
|
[201]
|
Gutiérrez-Gutiérrez, G., Sereno, M., Miralles, A., et al. (2010) Chemotherapy-Induced Peripheral Neuropathy: Clinical Features, Diagnosis, Prevention and Treatment Strategies. Clinical and Translational Oncology, 12, 81-91.
http://dx.doi.org/10.1007/S12094-010-0474-z
|
[202]
|
Quasthoff, S. and Hartung, H.P. (2002) Chemotherapy-Induced Peripheral Neuropathy. Journal of Neurology, 249, 9-17. http://dx.doi.org/10.1007/PL00007853
|
[203]
|
Rogawski, M.A. (2006) Molecular Targets versus Models for New Antiepileptic Drug Discovery. Epilepsy Research, 68, 22-28. http://dx.doi.org/10.1016/j.eplepsyres.2005.09.012
|
[204]
|
Cha, S. (2006) Update on Brain Tumor Imaging: From Anatomy to Physiology. American Journal of Neuroradiology, 27, 475-487.
|
[205]
|
Patsalos, P.N. (2004) Clinical Pharmacokinetics of Levetiracetam. Clinical Pharmacokinetics, 43, 707-724. http://dx.doi.org/10.2165/00003088-200443110-00002
|
[206]
|
Oberndorfer, S., Lindeck-Pozza, E., Lahrmann, H., et al. (2008) The End-of-Life Hospital Setting in Patients with Glioblastoma. Journal of Palliative Medicine, 11, 26-30.
http://dx.doi.org/10.1089/jpm.2007.0137
|
[207]
|
Lin, E., Rosenthal, M.A., Le, B.H. and Eastman, P. (2012) Neuro-Oncology and Palliative Care: A Challenging Interface. Journal of Neuro-Oncology, 14, iv3-iv7.
http://dx.doi.org/10.1093/neuonc/nos209
|
[208]
|
Walbert, T. (2014) Integration of Palliative Care into the Neuro-Oncology Practice: Patterns in the United States. Neuro-Oncology Practice, 1, 3-7.
http://dx.doi.org/10.1093/nop/npt004
|
[209]
|
Temel, J.S., Greer, J.A., Muzikansky, A., et al. (2010) Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 363, 733-742. http://dx.doi.org/10.1056/NEJMoa1000678
|
[210]
|
Palmer, J.L. and Fisch, M.J. (2005) Association between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center. Journal of Pain and Symptom Management, 29, 565-571. http://dx.doi.org/10.1016/j.jpainsymman.2004.11.007
|
[211]
|
Fleishaker, J.C., Pearson, L.K. and Peters, G.R. (1995) Phenytoin Causes a Rapid Increase in 6 Beta-Hydroxycortisol Urinary Excretion in Humans: A Putative Measure of CYP3A Induction. Journal of Pharmaceutical Sciences, 84, 292-294.
http://dx.doi.org/10.1002/jps.2600840305
|
[212]
|
Isojarvi, J.I.T. (1990) Serum Steroid Hormones and Pituitary Function in Female Epileptic Patients during Carbamazepine Therapy. Epilepsia, 31, 438-445.
http://dx.doi.org/10.1111/j.1528-1157.1990.tb05500.x
|
[213]
|
Brodie, M.J., Mintzer, S., Pack, A.M., et al. (2013) Enzyme Induction with Antiepileptic Drugs: Cause for Concern? Enzyme Induction with AEDs. Epilepsia, 54, 11-27.
http://dx.doi.org/10.1111/j.1528-1167.2012.03671.x
|
[214]
|
Isojarvi, J.I., Pakarinen, A.J., Rautio, A., et al. (1994) Liver Enzyme Induction and Serum Lipid Levels after Replacement of Carbamazepine with Oxcarbazepine. Epilepsia, 35, 1217-1220. http://dx.doi.org/10.1111/j.1528-1157.1994.tb01792.x
|
[215]
|
Anderson, G.D. (1998) A Mechanistic Approach to Antiepileptic Drug Interactions. Annals of Pharmacotherapy, 32, 554-563. http://dx.doi.org/10.1345/aph.17332
|
[216]
|
Abou-Khalil, B.W. (2009) The Far-Reaching Influence of Hepatic Enzyme-Inducing Antiepileptic Drugs. Epilepsy Currents, 9, 158-159.
http://dx.doi.org/10.1111/j.1535-7511.2009.01327.x
|
[217]
|
Leppik, I.E. (2004) Zonisamide: Chemistry, Mechanism of Action, and Pharmacokinetics. Seizure, 13, S10. http://dx.doi.org/10.1016/j.seizure.2004.04.016
|
[218]
|
Fuzier, R., Serres, I., et al., The French Network of Pharmacovigilance Centres (2013) Adverse Drug Reactions to Gabapentin and Pregabalin: A Review of the French Pharmacovigilance Database. Drug Safety, 36, 55-62. http://dx.doi.org/10.1007/s40264-012-0006-6
|
[219]
|
Tolman, J. and Faulkner, M. (2011) Treatment Options for Refractory and Difficult to Treat Seizures: Focus on Vigabatrin. Journal of Therapeutics and Clinical Risk Management, 7, 367-375. http://dx.doi.org/10.2147/TCRM.S8519
|